Abstract
Rising rates of opioid use among teenagers and young adults are a public health concern. Despite short durations of opioid use compared with those of adults, youth with opioid dependence have a host of co-occurring conditions, including polysubstance abuse, psychiatric disorders, hepatitis C infection, HIV risk, and high-risk sexual and criminal behaviors. Opioid-dependent youth typically are offered outpatient/residential treatment with brief detoxification, but one study showed that heroin users fare worse following residential treatment. Although abundant research supports the use of medication-assisted treatment for opioid-dependent adults, research is only recently emerging for youth. Buprenorphine, a partial opioid agonist, was proven safe and effective in improving abstinence from opioids in two controlled clinical trials. More research is needed to determine several clinically relevant areas: appropriate duration of agonist treatment, ways to enhance medication adherence, the value of integrated treatments for co-occurring conditions, and the role of opioid antagonists in opioid-dependent youth.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Johnston LD, O’Malley PM, Bachman JG, Schulenberg JE: Monitoring the Future: National Survey Results on Adolescent Drug Use: 1975–2006: Volume I, Secondary School Students. Bethesda, MD: National Institute on Drug Abuse; 2007 [NIH publication no. 07-6205.]
Substance Abuse and Mental Health Services Administration Office of Applied Studies: Drug Abuse Warning Network, 2006: National Estimates of Drug-related Emergency Department Visits. Rockville, MD: Substance Abuse and Mental Health Services Administration Office of Applied Studies: Drug Abuse Warning Network, 2006; 2008 [DAWN Series D-30, DHHS publication no. (SMA) 08-4339.] http://dawninfo.samhsa.gov/files/ED2006/DAWN2k6ED.pdf.
Substance Abuse and Mental Health Services Administration: Adapted by CESAR from Substance Abuse & Mental Health Data Archive (SAMHDA): Online analysis of the concatenated 1992-2004 TEDS data set, 2008. Available at http://www.icpsr.umich.edu/SAMHDA/. Accessed November 15, 2006.
Centers for Disease Control and Prevention: Viral hepatitis and injection drug users. Available at http://www.cdc.gov/IDU/hepatitis/viral_hep_drug_use.htm. Accessed September 15, 2007.
Ochoa KC, Hahn JA, Seal KH, Moss AR: Overdosing among young injection drug users in San Francisco. Addict Behav 2001, 26:453–460.
Substance Abuse and Mental Health Services Administration Office of Applied Studies: Treatment Episode Data Set (TEDS): 1995–2005. National Admissions to Substance Abuse Treatment Services. Rockville, MD: Substance Abuse and Mental Health Services Administration Office of Applied Studies; 2007 [DASIS series: S-37, DHHS publication no. (SMA) 07-4234.]
Hopfer CJ, Mikulich SK, Crowley TJ: Heroin use among adolescents in treatment for substance use disorders. J Am Acad Child Adolesc Psychiatry 2000, 39:1316–1323.
Clemmey P, Payne L, Fishman M: Clinical characteristics and treatment outcomes of adolescent heroin users. J Psychoactive Drugs 2004, 36:85–94.
Gordon SM, Mulvaney F, Rowan A: Characteristics of adolescents in residential treatment for heroin dependence. Am J Drug Alcohol Abuse 2004, 30:593–603.
Marsch LA, Bickel WK, Badger GJ, et al.: Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial. Arch Gen Psychiatry 2005, 62:1157–1164.
Subramaniam GA, Stitzer MA, Woody GE, et al.: Clinical characteristics of treatment seeking adolescents with opioid versus cannabis/alcohol use disorders. Drug Alcohol Depend 2009, 99:141–149.
Woody G, Poole S, Subramaniam GA, et al.: Extended medication-assisted therapy produces better outcomes than detoxification among opioid-addicted youth. JAMA 2008, 300:2003–2011.
Substance Abuse and Mental Health Services Administration Office of Applied Studies: Treatment episode data set, 1992–2006 (concatenated). Rockville, MD: Substance Abuse and Mental Health Services Administration Office of Applied Studies; 2008. Available at http://www.icpsr.umich.edu/cgi-bin/SDA/SAMHDA/hsda?samhda+tedsconcat. Accessed May 19, 2008.
Hopfer CJ, Khuri E, Crowley TJ, Hooks S: Adolescent heroin use: a review of the descriptive and treatment literature. J Subst Abuse Treat 2002, 23:231–237.
Mattick RP, Breen C, Kimber J, Davoli M: Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2003: CD002209.
Mattick RP, Kimber J, Breen C, Davoli M: Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2008: CD002207.
Amato L, Davoli M, Perucci CA, et al.: An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat 2005, 28:321–329.
Parrino M: State Methadone Treatment Guidelines, Treatment Improvement Protocol (TIP) Series 1. Rockville, MD: Substance Abuse and Mental Health Services Administration; 1993 [DHHS publication no. (SMA) 93-1991.]
Substance Abuse and Mental Health Services Administration: Buprenorphine: the Drug Addiction Treatment Act of 2000 (DATA 2000). Available at http://buprenorphine.samhsa.gov/index.html. Accessed May 5, 2009.
Fudala PJ, Bridge TP, Herbert S, et al.: Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med 2003, 349:949–958.
Walsh SL, Preston KL, Stitzer ML, et al.: Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 1994, 55:569–580.
US Food and Drug Administration: NDA 20-732. NDA 20-733. Available at http://www.fda.gov/cder/foi/label/2002/20732lbl.pdf. Accessed May 5, 2009.
Alho H, Sinclair D, Vuori E, Holopainen A: Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend 2007, 88:75–78.
New York Academy of Medicine: Physician Clinical Support System (PCSS)—buprenorphine: an educational resource for those treating patients with opioid dependence. 2005. Available at http://www.pcssbuprenorphine.org/. Accessed May 6, 2009.
Comer SD, Sullivan MA, Yu E, et al.: Injectable, sustainedrelease naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2006, 62:210–218.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Subramaniam, G.A., Fishman, M.J. & Woody, G. Treatment of opioid-dependent adolescents and young adults with buprenorphine. Curr Psychiatry Rep 11, 360–363 (2009). https://doi.org/10.1007/s11920-009-0054-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11920-009-0054-5